Vera kidney drug Trutakna shows strong final results in Phase 3 trial
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Vera kidney drug Trutakna shows strong final results in Phase 3 trial" is generating significant coverage in the Business category, with 8 articles from 8 distinct sources tracked by PULSE so far.
Outlets currently covering the story include fiercepharma.com, Pulse 2.0, marketscreener.com and HCPLive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 61d ago.
Quick answers
Why is "Vera kidney drug Trutakna shows strong final results in Phase 3 trial" trending?
Because 8 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry fiercepharma.com · 63d ago
- Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results Pulse 2.0 · 63d ago
- Vera Therapeutics Announces TRUTAKNA Stabilized eGFR and Prevented Kidney Disease Progression through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy marketscreener.com · 63d ago
- Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data HCPLive · 63d ago
- Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy Yahoo Finance · 63d ago
- Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens Investor's Business Daily · 63d ago
- Positive data positions Vera's IgA nephropathy drug Trutakna for full approval FirstWord Pharma · 63d ago
- Vera kidney drug Trutakna shows strong final results in Phase 3 trial STAT · 63d ago
Topics
Related trends
F.A.A. to Phase Out Floppy Disks in Air Traffic Control Towers
The Federal Aviation Administration plans to phase out floppy disks from air traffic control systems.
Vera Rubin Observatory spots the largest ultra-fast spinning asteroid yet
The Vera Rubin Observatory has detected the largest ultra-fast spinning asteroid known to science, challenging existing physical models.
Vera Rubin NVL72 Agentic Inference: 67x better Performance per Dollar
Nvidia reveals Vera Rubin architecture delivering massive performance gains and shifting data center design.
Vineland planning board votes to approve Phase 2 of controversial data center
Vineland approves Phase 2 of a massive AI data center as resident protests erupt and financial markets react to Nebius developments.
Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreak
Moderna launches its first human trial for a new mRNA Ebola vaccine targeting the specific strain spreading in the Democratic Republic of Congo.
Nvidia details its next-generation Vera CPU for AI, setting up challenge to AMD and Intel
Nvidia has unveiled the Vera CPU and Rubin GPU architectures, aiming for total chip dominance within AI data centers and challenging AMD and Intel.